Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with a specific reporting date of October 13, 2020. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively reports on specific share transactions executed on October 8, 2020.
| Transaction Type | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | £14.1900 | 1,604 shares |
Note: The total volume of 1,604 shares is the aggregate of individual transactions reported for Mr. N Hirons (12), Ms. S Jackson (1), Mr. D Jackson (2), Ms. V Whyte (33), Mr. I Whyte (1,015), and Ms. D Connor (523).
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance disclosures for share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) and were classified as initial notifications.
Investor Verification Checklist
- Verify that the share acquisitions were solely the result of dividend re-investment and not open market purchases.
- Confirm the transaction date of October 8, 2020, aligns with the dividend payment date.
- Check the London Stock Exchange (XLON) records for the execution price of £14.1900.
- Review the specific roles of the PDMRs and PCAs listed to ensure compliance with insider trading regulations.